Pfizer (PFE) Research & Development (2009 - 2026)

Pfizer (PFE) has reported Research & Development for 18 consecutive years, with $2.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 13.17% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $11.1 billion, a 27.14% decrease from a year earlier, with the FY2025 full-year figure at $10.4 billion, down 3.56% from the prior year.
• Research & Development was $2.8 billion for Q2 2026 at Pfizer, up from $2.5 billion in the prior quarter.
• Over five years, Research & Development peaked at $7.8 billion in Q3 2024 and troughed at $2.2 billion in Q1 2025.
• A 5-year average of $3.0 billion and a median of $2.6 billion in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development advanced 25.73% in 2022 and plunged 67.3% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $2.8 billion in 2022, then changed by 0.0% to $2.8 billion in 2023, then soared by 176.63% to $7.8 billion in 2024, then sank by 58.83% to $3.2 billion in 2025, then dropped by 12.38% to $2.8 billion in 2026.
• The last three Research & Development figures came in at $2.8 billion (Q2 2026), $2.5 billion (Q1 2026), and $3.2 billion (Q4 2025), per Business Quant data.